Anti-inflammatory Effect of Pentoxifylline. 2004

Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D010431 Pentoxifylline A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. Agapurin,BL-191,Oxpentifylline,Pentoxil,Torental,Trental,BL 191,BL191
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D017565 Sarcoidosis, Pulmonary Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431) Pulmonary Sarcoidosis,Pulmonary Sarcoidoses,Sarcoidoses, Pulmonary

Related Publications

Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai
February 1991, The American journal of the medical sciences,
Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai
November 2009, Der Anaesthesist,
Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai
March 2010, Digestive diseases and sciences,
Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai
December 2004, British journal of pharmacology,
Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai
April 2003, Pharmacological research,
Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai
March 1997, Clinical and experimental immunology,
Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai
February 2009, Journal of endourology,
Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai
June 2010, AIDS (London, England),
Ken-ichiro Inoue, and Hirohisa Takano, and Rie Yanagisawa, and Miho Sakurai
October 1961, Canadian Medical Association journal,
Copied contents to your clipboard!